GDRX GoodRx
- 7.030
- +0.020+0.29%
GoodRx News
TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $16
Leerink Partners Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $12
Wells Fargo Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
GoodRx Holdings: A Buy Rating on Strong Long-Term Care Growth and Strategic Market Positioning
Truist Financial Maintains GoodRx(GDRX.US) With Hold Rating
Progyny Stock Sinks 25% After Losing a Big Client. Why This Analyst Still Likes the Stock. -- Barrons.com
Wells Fargo Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
GoodRx Holdings Analyst Ratings
RBC Capital Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
RBC Capital Keeps Their Buy Rating on GoodRx Holdings (GDRX)
GoodRx Holdings: A Hold Rating Amid Mixed Performance and Market Challenges
Analysts Conflicted on These Healthcare Names: GoodRx Holdings (GDRX), NewAmsterdam Pharma Company (NAMS) and UniQure (QURE)
GoodRx Holdings Analyst Ratings
GoodRx Holdings (GDRX) Gets a Buy From TD Cowen
Truist Financial Keeps Their Hold Rating on GoodRx Holdings (GDRX)
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), GoodRx Holdings (GDRX) and Tenaya Therapeutics (TNYA)
GoodRx Holdings: Hold Rating Amidst Operational Strengths and Market Uncertainties
Steady Growth and Resilience Drive Buy Rating for GoodRx Holdings
GoodRx Holdings: A Balanced View Amidst Sector Challenges and Management Discipline
GoodRx Holdings Faces Headwinds: Sell Rating Justified by Customer Decline and Revenue Concerns
Analysis
Price Target
No Data
No Data